2022³â Á¦14ȸ ´ëÇÑÅðÇ༺½Å°æÁúȯÇÐȸ Çмú´ëȸ : 2022-09-24±³À°ÀÏÀÚ : 2022-09-24
±³À°Àå¼Ò : ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ
±³À°ÁÖÁ¦ :
2022³â Á¦14ȸ ´ëÇÑÅðÇ༺½Å°æÁúȯÇÐȸ Çмú´ëȸÁÖÃÖ±â°ü : ´ëÇѽŰæ°úÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑÅðÇ༺½Å°æÁúȯÇÐȸ
´ã´çÀÚ : À̹̼±
¿¬¶ôó : 02-440-7240
À̸ÞÀÏ :
office.ksnd@gmail.com ±³À°Á¾·ù : ½Å°æ°ú
Âü¼®¿¹»óÀοø : 250¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 55ºÐ
¼¼ºÎ¼ö°·á : 100,000¿ø
ºñ°í »çÀüµî·Ï(ÁØȸ¿ø 3¸¸¿ø, Á¤È¸¿ø/ÀÌ»çÁø 5¸¸¿ø), ´çÀϵî·Ï(ÁØȸ¿ø 5¸¸¿ø, Á¤È¸¿ø/ÀÌ»çÁø 7¸¸¿ø), ºñȸ¿ø(ÁØȸ¿ø±Þ 8¸¸¿ø, Á¤È¸¿ø±Þ 10¸¸¿ø)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:00~09:30 Registration ()
±âŸ 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:30~09:40 Opening Remark ÃÖº´¿Á(¼º±Õ°ü´ë)
±³À°½Ã°£ 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:40~09:55 Alzheimer disease ¹Ú¿µÈ£(ºÐ´ç¼¿ï´ëº´¿ø)
±³À°½Ã°£ 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:55~10:10 Parkinson¡¯s disease ½Åä¿ø(Ãæ³²´ë)
±³À°½Ã°£ 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 10:10~10:25 Motor neuron disease ÃÖ¼®Áø(¼¿ï´ë)
±³À°½Ã°£ 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 10:25~10:40 Peripheral nerve disease À±º°¾Æ(µ¿¾Æ´ë)
ÈÞ½Ä 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 10:40~11:00 Break ()
±³À°½Ã°£ 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 11:00~11:40 Impaired dynamics of phase transition and neuro-inflammation in neurodegenerative diseases ±è½ÂÇö(ÇѾç´ë)
±³À°½Ã°£ 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 11:40~12:20 Proteostasis and Pathogenic Mechanism of Alzheimer¡¯s Disease Á¤¿ë±Ù(¼¿ï´ë)
½Ä»ç 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 12:20~13:20 ÃÑȸ ¹× Lunch ()
±³À°½Ã°£ 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ A 13:25~13:50 The CDK4/6 inhibitor abemaciclib mesylate regulates A¥â/tau pathology, neuroinflammation and Ab/LPS-mediated cognitive impairment ÇãÇâ¼÷(Çѱ¹³ú¿¬±¸¿ø)
±³À°½Ã°£ 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ A 13:50~14:15 The Critical Role of Nurr1 as a Mediator and Therapeutic Target in Alzheimer's Disease-related Pathogenesis ¹®¹ÎÈ£(°Ç¾çÀÇ´ë)
±³À°½Ã°£ 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ A 14:15~14:40 Alteration of intestinal immune cells in the APP/PS1 mice with DSS-induced colitis ¾ç½ÂÈÆ(µ¿±¹´ë)
±³À°½Ã°£ 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ B 13:20~14:40 How to develop and manage biotech companies TBA()
±âŸ 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 14:40~15:20 Guided Poster session ÇмúÀ§¿ø()
±³À°½Ã°£ 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ A 15:20~15:40 High-sensitivity immunoassay of beta-amyloid contained in plasma extracellular vesicles in Alzheimer's disease patients 3 °ÁöÀ±(KIST)
±³À°½Ã°£ 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ A 15:40~16:00 Blood biomarkers in AD: current and future landscape °í¼ºÈ£(ÇѾç´ë)
±³À°½Ã°£ 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ A 16:00~16:20 Neuroimaging markers in neurodegeneration Á¤¿ë(KAIST)
±³À°½Ã°£ 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ B 15:20~15:40 Peripheral nerve disease modeling ±è¿ëÁØ(°æÈñ´ë)
±³À°½Ã°£ 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ B 15:40~16:00 Mouse models for Amyotrophic Lateral Sclerosis È«¿µºó(µ¿¾Æ´ëÇб³)
±³À°½Ã°£ 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ B 16:00~16:20 Modeling Alzheimer's disease using human iPSC-derived brain organoids ¼Áø¼ö(DGIST)
ÈÞ½Ä 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 16:20~16:30 Break ()
±âŸ 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 16:30~17:20 Oral presentation session À̽ÂÀç(¼¿ïÀÇ´ë)
±âŸ 09-24 ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 17:20~17:30 Award & Closing ()